Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients
Author:
Funder
Ministry of Science and Technology
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference21 articles.
1. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res.,2004
2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5;Liu;Cancer Res.,2006
3. Sorafenib: a review of its use in advanced hepatocellular carcinoma;Keating;Drugs,2009
4. Modulation of autophagy by sorafenib: effects on treatment response;Prieto-Domínguez;Front. Pharmacol.,2016
5. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors;Strumberg;Oncologist,2007
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma;Biomedicine & Pharmacotherapy;2022-09
2. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression;The Kaohsiung Journal of Medical Sciences;2021-11-16
3. Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment;The Kaohsiung Journal of Medical Sciences;2020-04-29
4. RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients;Open Medicine;2020-03-08
5. Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules;The Kaohsiung Journal of Medical Sciences;2020-03-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3